At Goodness Growth Holdings, we are determined to find better answers for the patients we serve. We are driven to keep the “medical” in medical cannabis by participating in establishing and applying evidence-based practices. We strive to guide our consumers and medical patients with honest and accurate information regarding therapeutic cannabis use and product safety. High-quality research is key in reaching these goals.
Most US states have now legalized some form of cannabis use. As a physician-led and founded company, we seek and support the guidance of scientists and clinicians. Currently, the U.S. federal government lists cannabis as a Schedule I Controlled Substance, meaning the federal government classifies it as having no accepted medical use and is unsafe to use even under medical supervision. These policies can stop the ability of clinicians, researchers, and patients to access the reliable information they need to stay informed on the benefits of medical cannabis and cannabis research.
We at Goodness Growth Holdings thank you for your interest and investment in medical cannabis research!Download PDF
Vireo Health is on the forefront of collaborative, high-fidelity research around scientifically accurate cannabis research.
In New York, Vireo Health has partnered with Dr. Julia Arnsten and her team of opioid research experts at the Albert Einstein College of Medicine and Montefiore Health System, playing an active role in study development for a unique National Institute of Health R01 $3.8 million research grant for medical marijuana research. Our White Plains dispensary will serve as the hub for recruitment in this first long-term study to investigate whether treatment with medical marijuana can lead to a reduction in opioid use in adults with chronic pain.
This study is a randomized double-blind controlled trial of vouchers for discounted medical cannabis soft-gel capsules. Participants must suffer from chronic pain, be over 18 years old, and newly certified for medical cannabis within 90 days. The trial will last 14 weeks and patients will be randomized to a discounted voucher for one of the three soft-gel capsule medical cannabis products or the placebo soft-gel capsule product.
Vireo Health is working with Drs. Monica Luciana and Angela Birnbaum on a pre-post assessment of 90 adults, ages 35 to 55, who are prescribed medical cannabis to treat intractable pain. Outcome variables will include (a) neural structure measured using T1-weighted and T2-weighted MRI scans as well as function measured using functional resting state and task-based MRI, (b) cognition (with an emphasis on learning, memory and executive functions), and (c) mental health, including symptoms of anxiety and depression. Pain relief, use of concomitant medications including prescribed opiates, and quality of life indices will also be examined as secondary outcomes. Participants are actively being from dispensaries in the State of Minnesota and will be asked to complete a 4-hour battery of measures prior to ingesting the first prescribed medical cannabis dose. This exciting and unique trial will examine the neurobehavioral impacts of medical cannabis on adults using cannabis for chronic pain.
Vireo Health’s leading scientific minds have been published in esteemed white papers and journals across the medical zeitgeist. Our goal is to educate and inspire new alternative medicines through legitimate scientific processes.